TABLE 1.
Baseline characteristics by EVR status1
| EVR status |
||||
| Total (n = 144) | EVR (n = 76) | Non-EVR (n = 68) | P value | |
| Sex, male [n (%)] | 119 (82.6) | 66 (86.8) | 53 (77.9) | 0.192 |
| Age (y) | 0.0063 | |||
| Median | 48 | 47 | 49 | |
| Q1, Q3 | 41.5, 52.0 | 40, 50 | 44, 53 | |
| Race-ethnicity [n (%)] | 0.0142 | |||
| White, non-Hispanic | 47 (32.6) | 33 (43.4) | 14 (20.6) | |
| Black, non-Hispanic | 76 (52.8) | 33 (43.4) | 43 (63.2) | |
| Hispanic | 21 (14.6) | 10 (13.2) | 11 (16.2) | |
| BMI (kg/m2) | 0.773 | |||
| Median | 25.7 | 25.5 | 25.9 | |
| Q1, Q3 | 22.8, 29.3 | 23.0, 28.5 | 22.7, 29.6 | |
| IV drug use history [n (%)] | 91 (63.2) | 44 (57.9) | 47 (69.1) | 0.172 |
| Cirrhosis [n (%)] | 18 (12.5) | 5 (6.6) | 13 (19.1) | 0.0412 |
| Platelet count (103/mm3) | 0.143 | |||
| Median | 206 | 209 | 198 | |
| Q1, Q3 | 159, 250 | 172, 257 | 155, 236 | |
| Alkaline phosphatase (U/L)4 | 0.823 | |||
| Median | 94 | 92 | 96 | |
| Q1, Q3 | 78, 120 | 74, 124 | 79, 114 | |
| Albumin (g/dL)4 | 0.0033 | |||
| Median | 4.15 | 4.30 | 4 | |
| Q1, Q3 | 3.90, 4.40 | 4.00, 4.50 | 3.80, 4.30 | |
| GFR (mL · min−1 · 1.73 m−2)5 | 0.823 | |||
| Median | 101.5 | 99.8 | 104.4 | |
| Q1, Q3 | 84.3, 113.5 | 87.1, 111.8 | 81.7, 113.8 | |
| HOMA-IR (mg/dL · μU · mL−1 · 405−1)6 | ||||
| Median | 3.15 | 3.37 | 2.76 | 0.442 |
| Q1, Q3 | 1.76, 5.10 | 1.88, 5.51 | 1.59, 4.65 | |
| Baseline CD4 (cells/mm3) | 0.973 | |||
| Median | 507 | 507 | 504 | |
| Q1, Q3 | 380, 703 | 384, 645 | 356, 719 | |
| Nadir CD4 (cells/mm3) | 0.123 | |||
| Median | 247 | 205 | 258 | |
| Q1, Q3 | ||||
| Baseline HIV-1 RNA [n (%)] | 1.002 | |||
| Undetectable, <50 copies/mL | 101 (70.1) | 53 (69.7) | 48 (70.6) | |
| Baseline log10 HCV RNA (IU/mL) | 0.0432 | |||
| Median | 6.54 | 6.50 | 6.60 | |
| Q1, Q3 | 6.15, 6.88 | 5.88, 6.87 | 6.40, 6.89 | |
| IL28B genotype [n (%)]7 | 0.0248 | |||
| TT | 23 (21.5) | 7 (12.5) | 16 (31.4) | |
| CT | 49 (45.8) | 27 (48.2) | 22 (43.1) | |
| CC | 35 (32.7) | 22 (39.3) | 13 (25.5) | |
| Season, summer [n (%)]9 | 73 (50.7) | 37 (48.7) | 36 (52.9) | 0.622 |
| Antiretroviral medication use [n (%)] | ||||
| HAART | 114 (79.2) | 62 (81.6) | 52 (76.5) | 0.542 |
| Ritonavir | 55 (38.2) | 31 (40.8) | 24 (35.3) | 0.612 |
| 25(OH)D (ng/mL) | 0.233 | |||
| Median | 22.5 | 25 | 20 | |
| Q1, Q3 | 14.0, 29.0 | 13.0, 30.5 | 14.0, 27.5 | |
1
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; EVR, early virologic response; GFR, glomerular filtration rate; HAART, highly active antiretroviral therapy; HCV, hepatitis C virus; IV, intravenous; Q1, first quartile (25th percentile); Q3, third quartile (75th percentile); 25(OH)D, 25-hydroxyvitamin D.
2
Fisher's exact test.
3
Wilcoxon's test.
4
Total n = 142 (n = 75 for EVR and n = 67 for non-EVR).
5
CKD-EPI equation.
6
Total n = 70 (n = 37 for EVR and 33 for non-EVR).
7
Total n = 107 (n = 56 for EVR and n = 51 for non-EVR).
8
Exact Cochran-Armitage trend test.
9
June–November.